"10.1371_journal.ppat.1003754","plos pathogens","2013-11-21T00:00:00Z","Devin Sok; Uri Laserson; Jonathan Laserson; Yi Liu; Francois Vigneault; Jean-Philippe Julien; Bryan Briney; Alejandra Ramos; Karen F Saye; Khoa Le; Alison Mahan; Shenshen Wang; Mehran Kardar; Gur Yaari; Laura M Walker; Birgitte B Simen; Elizabeth P St. John; Po-Ying Chan-Hui; Kristine Swiderek; Stephen H Kleinstein; Galit Alter; Michael S Seaman; Arup K Chakraborty; Daphne Koller; Ian A Wilson; George M Church; Dennis R Burton; Pascal Poignard","Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, United States of America; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America; Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, United States of America; Department of Mathematics, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America; Department of Computer Science, Stanford University, Stanford, California, United States of America; Biomedical Informatics Training Program, Stanford University School of Medicine, Stanford, California, United States of America; AbVitro Inc., Boston, Massachusetts, United States of America; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America; International AIDS Vaccine Initiative, New York, New York, United States of America; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, Massachusetts, United States of America; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America; 454 Life Sciences â€“ A Roche Company, Branford, Connecticut, United States of America; Theraclone Sciences, Inc., Seattle, Washington, United States of America; Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America; Department of Chemistry, Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: DS UL JL YL FV JPJ BB LMW DRB PP. Performed the experiments: DS UL JL YL FV JPJ BB AR KFS KL AM BBS EPSJ PYCH KS MSS. Analyzed the data: DS UL JL YL FV JPJ BB SW MK AKC IAW DRB PP. Contributed reagents/materials/analysis tools: GY SHK. Wrote the paper: DS UL JL YL FV JPJ BB IAW DRB PP. Supervised research: GA DK GMC.","Authors BBS and EPSJ are employed by 454 Life Sciences - Roche Sequencing Solutions. Authors PYCH and KS are employed by Theraclone-Sciences. FV is employed by, UL and GMC are advisors to, and FV, UL, and GMC own stock in AbVitro, which owns intellectual property in various immune sequencing technologies. The IAVI and Theraclone hold U.S. patent 61/515,528 on the PGT antibodies. All other authors declare no competing interests. This does not alter our adherence to all PLOS Pathogens policies on sharing data and materials.","2013","11","Devin Sok","DS",28,FALSE,10,16,13,10,TRUE,TRUE,FALSE,0,NA,FALSE
